Pfizer的RSV疫苗ABRYSVO为18-59岁的成年人和孕妇获得欧盟批准。 Pfizer's RSV vaccine, ABRYSVO, gets EU approval for adults aged 18-59 and pregnant women.

欧洲联盟委员会核准了辉瑞公司针对18至59岁成年人的RSV疫苗ABRYSVO,扩大了以前对60岁及60岁以上成年人的核准范围。 The European Commission has approved Pfizer's RSV vaccine, ABRYSVO, for adults aged 18 to 59, expanding its previous approval for those 60 and older. 这一批准是基于第3阶段临床试验的积极成果,旨在预防RSV引起的下呼吸道疾病。 This approval is based on positive results from a phase 3 clinical trial and aims to prevent lower respiratory tract disease caused by RSV. 24周至36周的孕妇也可以使用这种疫苗来保护6个月以下的婴儿。 The vaccine can also be used by pregnant women between weeks 24 and 36 to protect infants up to six months old.